SRR5088822
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- SPERMATOGENESIS+0.300
- XENOBIOTIC_METABOLISM+0.300
- BILE_ACID_METABOLISM+0.200
- E2F_TARGETS+0.200
- ESTROGEN_RESPONSE_LATE+0.200
- KRAS_SIGNALING_DN+0.200
- MYC_TARGETS_V2+0.200
- PANCREAS_BETA_CELLS+0.200
- ANGIOGENESIS+0.100
- COAGULATION+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.400
- IL6_JAK_STAT3_SIGNALING-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
- NOTCH_SIGNALING-0.300
- PI3K_AKT_MTOR_SIGNALING-0.300
- PROTEIN_SECRETION-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- TGF_BETA_SIGNALING-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
- UV_RESPONSE_DN-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-UY-A9PE-01A-11R-A38B-07 | — | — | 0.812 |
| 2 | TCGA-NK-A7XE-01A-12R-A405-07 | — | cohortSQ1 | 0.777 |
| 3 | R283 | — | — | 0.770 |
| 4 | R227 | — | — | 0.764 |
| 5 | SRR8942989 | — | — | 0.748 |
| 6 | SRR33532828 | — | B | 0.745 |
| 7 | GSM5359440 | — | — | 0.736 |
| 8 | TCGA-43-2578-01A-01R-0851-07 | — | cohortMD1 | 0.730 |
| 9 | TCGA-53-A4EZ-01A-12R-A24X-07 | — | cohortA3 | 0.725 |
| 10 | DRR168608 | — | — | 0.720 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |